Skip to main content
SpringerLink
Log in

Peripheral Nerve Amyloidosis

  • Chapter
Amyloid and Related Disorders

Part of the book series: Current Clinical Pathology ((CCPATH))

  • 1417 Accesses

Abstract

In this chapter, we provide an overview of peripheral nerve amyloidosis, focusing on both universal and subtype-specific pathologic features. In the great majority of cases of amyloidosis involving peripheral nerve, amyloid fibrils are either formed by immunoglobulin light chains stemming from systemic plasma cell dyscrasia (primary or AL amyloidosis) or else mutant transthyretin (TTR). Peripheral neural involvement is a common feature and hallmark of amyloidosis—reported to occur in 17–35 % of AL amyloidosis cases, and in a majority of cases of TTR amyloidosis. Other than AL and TTR amyloidosis, only rare kindreds with a short list of amyloidogenic mutations, such as gelsolin and apolipoprotein A1, are known to develop amyloid neuropathy. Pathologic features are outlined in detail in the context of these amyloid subtypes, and clinical details and issues are reported briefly.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kyle A, Kelly JJ, Dyck PJ. Amyloidosis and neuropathy. In: Dyck P, editor. Peripheral neuropathies. Philadelphia, PA: Saunders; 2005. p. 2427–51.

    Chapter  Google Scholar 

  2. Adams D. Hereditary and acquired amyloid neuropathies. J Neurol. 2001;248(8):647–57.

    Article  CAS  PubMed  Google Scholar 

  3. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36(4):411–23.

    Article  CAS  PubMed  Google Scholar 

  4. Klein CJ, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol. 2011;68(2):195–9.

    Article  PubMed Central  PubMed  Google Scholar 

  5. De Navasquez S, Treble HA. A case of primary generalized amyloid disease with involvement of the nerves. Brain. 1938;61:12.

    Article  Google Scholar 

  6. De Bruyn RS, Stern RO. A case of the progressive hypertrophic polyneuritis of Dejerine and Sottas, with pathological examination. Brain. 1929;52(1):23.

    Article  Google Scholar 

  7. Krucke W. Histopathologie der Polyneuritis und Polyneuropathie. Dtsch Z Nervenheilkd. 1959;180:1–39.

    Article  Google Scholar 

  8. Krucke W. Zur pathologischen Anatomie der Paramyloidose. Acta Neuropathol (Berl). 1963;Suppl. II:74–93.

    Google Scholar 

  9. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75(3):408–27.

    Article  CAS  PubMed  Google Scholar 

  10. Horta JS, Trincao R. Anatomie pathologique de la paramyloidose de “type Portugais”. Acta Neuropathol (Berl). 1963;Suppl. II:54–65.

    Google Scholar 

  11. Dyck PJ, Lambert EH. Dissociated sensation in amyloidosis. Compound action potential, quantitative histologic and teased-fiber, and electron microscopic studies of sural nerve biopsies. Arch Neurol. 1969;20(5):490–507.

    Article  CAS  PubMed  Google Scholar 

  12. Cohen AS, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature. 1959;183(4669):1202–3.

    Article  CAS  PubMed  Google Scholar 

  13. Cohen AS, Shirahama T, Skinner M. Electron microscopy of amyloid. In: Harris I, editor. Electron microscopy of protein. London: Academic; 1982. p. 165–205.

    Google Scholar 

  14. Rajani B, Rajani V, Prayson RA. Peripheral nerve amyloidosis in sural nerve biopsies: a clinicopathologic analysis of 13 cases. Arch Pathol Lab Med. 2000;124(1):114–8.

    CAS  PubMed  Google Scholar 

  15. Kelly JJ. Neurologic complications of primary systemic amyloidosis. Rev Neurol Dis. 2006;3(4):173–81.

    PubMed  Google Scholar 

  16. Consales A, et al. Amyloidoma of the brachial plexus. Surg Neurol. 2003;59(5):418–23. Discussion 423.

    Article  PubMed  Google Scholar 

  17. Gabet JY, et al. [Amyloid pseudotumor of the sciatic nerve]. Rev Neurol. 1989;145(12):872–6.

    CAS  PubMed  Google Scholar 

  18. Haridas A, et al. Primary isolated amyloidoma of the lumbar spine causing neurological compromise: case report and literature review. Neurosurgery. 2005;57(1):E196. Discussion E196.

    Article  PubMed  Google Scholar 

  19. Ladha SS, et al. Isolated amyloidosis presenting with lumbosacral radiculoplexopathy: description of two cases and pathogenic review. J Peripher Nerv Syst. 2006;11(4):346–52.

    Article  PubMed  Google Scholar 

  20. Laeng RH, et al. Amyloidomas of the nervous system: a monoclonal B-cell disorder with monotypic amyloid light chain lambda amyloid production. Cancer. 1998;82(2):362–74.

    Article  CAS  PubMed  Google Scholar 

  21. Pizov G, Soffer D. Amyloid tumor (amyloidoma) of a peripheral nerve. Arch Pathol Lab Med. 1986;110(10):969–70.

    CAS  PubMed  Google Scholar 

  22. Porchet F, Sonntag VK, Vrodos N. Cervical amyloidoma of C2. Case report and review of the literature. Spine. 1998;23(1):133–8.

    Article  CAS  PubMed  Google Scholar 

  23. Unal F, et al. Skull base amyloidoma. Case report. J Neurosurg. 1992;76(2):303–6.

    Article  CAS  PubMed  Google Scholar 

  24. Wang AK, et al. Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc. 2008;83(11):1226–30.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Meretoja J. Genetic aspects of familial amyloidosis with corneal lattice dystrophy and cranial neuropathy. Clin Genet. 1973;4(3):173–85.

    Article  CAS  PubMed  Google Scholar 

  26. Luttmann RJ, et al. Hereditary amyloidosis of the Finnish type in a German family: clinical and electrophysiological presentation. Muscle Nerve. 2010;41(5):679–84.

    PubMed  Google Scholar 

  27. Tracy JK, Klein CJ. Corneal lattice dystrophy, facial weakness and sensorimotor polyneuropathy-gelsolin amyloidosis. In: Dyck PJ, Amrani K, Klein CJ, Dyck PJB, Low PA, Engelstad J, Spinner RJ editors.Companion to peripheral neuropathy: illustrated cases and new developments. Philadelphia, PA: Saunders; 2011, p. 155–8.

    Google Scholar 

  28. Brett M, et al. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain. 1999;122(Pt 2):183–90.

    Article  PubMed  Google Scholar 

  29. Klein CJ, et al. Transthyretin amyloidosis (serine 44) with headache, hearing loss, and peripheral neuropathy. Neurology. 1998;51(5):1462–4.

    Article  CAS  PubMed  Google Scholar 

  30. Andrews TR, et al. Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy. Mayo Clin Proc. 2002;77(12):1287–90.

    Article  PubMed  Google Scholar 

  31. Kernohan JW, Woltman HW. Amyloid neuritis. Arch Neurol Psychiatr. 1942;47:132–40.

    Article  Google Scholar 

  32. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A. 1994;91(25):12243–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Simmons LK, et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol. 1994;45(3):373–9.

    CAS  PubMed  Google Scholar 

  34. Garces-Sanchez M, et al. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle Nerve. 2008;37(4):490–5.

    Article  CAS  PubMed  Google Scholar 

  35. Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am. 1999;13(6):1235–48.

    Article  CAS  PubMed  Google Scholar 

  36. Krebs MR, et al. The formation of spherulites by amyloid fibrils of bovine insulin. Proc Natl Acad Sci U S A. 2004;101(40):14420–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Unal A, Sutlap PN, Kyyyk M. Primary solitary amyloidoma of thoracic spine: a case report and review of the literature. Clin Neurol Neurosurg. 2003;105(3):167–9.

    Article  CAS  PubMed  Google Scholar 

  38. Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine (Baltimore). 1975;54(4):271–99.

    Article  CAS  Google Scholar 

  39. Krishnan J, et al. Tumoral presentation of amyloidosis (amyloidomas) in soft tissues. A report of 14 cases. Am J Clin Pathol. 1993;100(2):135–44.

    CAS  PubMed  Google Scholar 

  40. Solomon A, Murphy CL, Westermark P. Unreliability of immunohistochemistry for typing amyloid deposits. Arch Pathol Lab Med. 2008;132(1):14. Author reply 14–5.

    PubMed  Google Scholar 

  41. Lachmann HJ, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346(23):1786–91.

    Article  CAS  PubMed  Google Scholar 

  42. Vrana JA, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–9.

    Article  CAS  PubMed  Google Scholar 

  43. Solomon A, Kyle A, Frangione B. Light chain variable region subgroups of monoclonal immunoglobulins in amyloidosis-AL. In: Glenner GG, Osserman EF, Benditt EP, editors. Amyloidosis. New York: Plenum; 1986.

    Google Scholar 

  44. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(2):180–6.

    Article  PubMed  Google Scholar 

  45. Gertz MA, Kyle RA. Primary systemic amyloidosis—a diagnostic primer. Mayo Clin Proc. 1989;64(12):1505–19.

    Article  CAS  PubMed  Google Scholar 

  46. Kyle RA, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–9.

    Article  CAS  PubMed  Google Scholar 

  47. Davids MS, Murali MR, Kuter DJ. Serum free light chain analysis. Am J Hematol. 2010;85(10):787–90.

    Article  PubMed  Google Scholar 

  48. Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med. 1998;104(3):232–7.

    Article  CAS  PubMed  Google Scholar 

  49. Kyle RA, Gertz MA. Systemic amyloidosis. Crit Rev Oncol Hematol. 1990;10(1):49–87.

    Article  CAS  PubMed  Google Scholar 

  50. Buxbaum JN. The systemic amyloidoses. Curr Opin Rheumatol. 2004;16(1):67–75.

    Article  CAS  PubMed  Google Scholar 

  51. Duston MA, et al. Peripheral neuropathy as an early marker of AL amyloidosis. Arch Intern Med. 1989;149(2):358–60.

    Article  CAS  PubMed  Google Scholar 

  52. Kyle RA, Greipp PR, O’Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 1986;68(1):220–4.

    CAS  PubMed  Google Scholar 

  53. Vallat JM, et al. Intranervous immunoglobulin deposits: an underestimated mechanism of neuropathy. Muscle Nerve. 2008;38(1):904–11.

    Article  PubMed  Google Scholar 

  54. Moorhouse DF, Fox RI, Powell HC. Immunotactoid-like endoneurial deposits in a patient with monoclonal gammopathy of undetermined significance and neuropathy. Acta Neuropathol. 1992;84(5):484–94.

    Article  CAS  PubMed  Google Scholar 

  55. Lamarca J, Casquero P, Pou A. Mononeuritis multiplex in Waldenstrom’s macroglobulinemia. Ann Neurol. 1987;22(2):268–72.

    Article  CAS  PubMed  Google Scholar 

  56. Figueroa JJ, et al. Amyloid-like IgM deposition neuropathy: a distinct clinico-pathologic and proteomic profiled disorder. J Peripher Nerv Syst. 2012;17(2):182–90.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Valleix S, et al. Hereditary systemic amyloidosis due to Asp76Asn variant beta2-microglobulin. N Engl J Med. 2012;366(24):2276–83.

    Article  CAS  PubMed  Google Scholar 

  58. Kang GH, et al. A case of a senile systemic amyloidosis patient presenting with angina pectoris and dilated cardiomyopathy. Korean Circ J. 2011;41(4):209–12.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Pitkanen P, Westermark P, Cornwell 3rd GG. Senile systemic amyloidosis. Am J Pathol. 1984;117(3):391–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  60. Kyle RA, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med. 1996;101(4):395–400.

    Article  CAS  PubMed  Google Scholar 

  61. Sueyoshi T, et al. Spinal multifocal amyloidosis derived from wild-type transthyretin. Amyloid. 2011;18(3):165–8.

    Article  CAS  PubMed  Google Scholar 

  62. Stangou AJ, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation. 1998;66(2):229–33.

    Article  CAS  PubMed  Google Scholar 

  63. Olofsson BO, et al. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation. 2002;73(5):745–51.

    Article  PubMed  Google Scholar 

  64. Dubrey SW, et al. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation. 1997;64(1):74–80.

    Article  CAS  PubMed  Google Scholar 

  65. Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75(4):324–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Thomas PK. Genetic factors in amyloidosis. J Med Genet. 1975;12(4):317–26.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  67. Varga J, Wohlgethan JR. The clinical and biochemical spectrum of hereditary amyloidosis. Semin Arthritis Rheum. 1988;18(1):14–28.

    Article  CAS  PubMed  Google Scholar 

  68. Ikeda K, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2008;70(17):1576. Author reply 1576–7.

    Article  CAS  PubMed  Google Scholar 

  69. Plante-Bordeneuve V, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007;69(7):693–8.

    Article  CAS  PubMed  Google Scholar 

  70. Cappellari M, et al. Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst. 2011;16(2):119–29.

    Article  PubMed  Google Scholar 

  71. Misu K, et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain. 1999;122(Pt 10):1951–62.

    Article  PubMed  Google Scholar 

  72. Meretoja J, Teppo L. Histopathological findings of familial amyloidosis with cranial neuropathy as principal manifestation. Report on three cases. Acta Pathol Microbiol Scand A. 1971;79(5):432–40.

    CAS  PubMed  Google Scholar 

  73. Chen CD, et al. Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J. 2001;20(22):6277–87.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  74. Kiuru-Enari S, et al. Neuromuscular pathology in hereditary gelsolin amyloidosis. J Neuropathol Exp Neurol. 2002;61(6):565–71.

    CAS  PubMed  Google Scholar 

  75. Kiuru S. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid. 1998;5(1):55–66.

    Article  CAS  PubMed  Google Scholar 

  76. de Sousa MM, et al. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol. 2000;156(6):1911–7.

    Article  PubMed Central  PubMed  Google Scholar 

  77. Joy T, et al. APOA1 related amyloidosis: a case report and literature review. Clin Biochem. 2003;36(8):641–5.

    Article  CAS  PubMed  Google Scholar 

  78. Nichols WC, et al. A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics. 1990;8(2):318–23.

    Article  CAS  PubMed  Google Scholar 

  79. Van Allen MW, Frohlich JA, Davis JR. Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy, and peptic ulcer. Neurology. 1969;19(1):10–25.

    Article  PubMed  Google Scholar 

  80. Booth DR, et al. A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM. 1995;88(10):695–702.

    CAS  PubMed  Google Scholar 

  81. Soutar AK, et al. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci U S A. 1992;89(16):7389–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. Persey MR, et al. Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int. 1998;53(2):276–81.

    Article  CAS  PubMed  Google Scholar 

  83. Hamidi Asl K, et al. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun. 1999;257(2):584–8.

    Article  CAS  PubMed  Google Scholar 

  84. Kumar SK, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86(1):12–8.

    Article  PubMed Central  PubMed  Google Scholar 

  85. Dispenzieri A, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103(10):3960–3.

    Article  CAS  PubMed  Google Scholar 

  86. Takei Y, et al. Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: outcomes of living donor liver transplantations. Intern Med. 2005;44(11):1151–6.

    Article  PubMed  Google Scholar 

  87. Yamamoto S, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant. 2007;7(11):2597–604.

    Article  CAS  PubMed  Google Scholar 

  88. Jono H, et al. Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis. Biochem J. 2011;437(1):35–42.

    Article  CAS  PubMed  Google Scholar 

  89. Adams D, et al. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep. 2014;14(3):435.

    Article  PubMed  Google Scholar 

  90. Tojo K, et al. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res. 2006;56(4):441–9.

    Article  CAS  PubMed  Google Scholar 

  91. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13(4):236–49.

    Article  CAS  PubMed  Google Scholar 

  92. Berk JL, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–67.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  93. Bulawa CE, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  94. Coelho T, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  95. Benson MD, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006;33(5):609–18.

    Article  CAS  PubMed  Google Scholar 

  96. Sacchettini JC, Kelly JW. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov. 2002;1(4):267–75.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kennedy Laboratory, Department of Neurology, University of Minnesota, Diehl Hall J108, 505 Essex St. SE, Minneapolis, MN, 55455, USA

    Adam J. Loavenbruck MD, MS

  2. Peripheral Nerve Laboratory, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA

    JaNean K. Engelstad MS & Christopher J. Klein MD

Authors
  1. Adam J. Loavenbruck MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. JaNean K. Engelstad MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher J. Klein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam J. Loavenbruck MD, MS .

Editor information

Editors and Affiliations

  1. Department of Pathology, Loyola University Medical Center, Maywood, Illinois, USA

    Maria M. Picken

  2. Department of Pathology, LSU Health Shreveport, Shreveport, Louisiana, USA

    Guillermo A. Herrera

  3. Department of Pathology and Laboratory Medicine, Department of Pathology and Laboratory Medicine, New York, New York, USA

    Ahmet Dogan

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Loavenbruck, A.J., Engelstad, J.K., Klein, C.J. (2015). Peripheral Nerve Amyloidosis. In: Picken, M., Herrera, G., Dogan, A. (eds) Amyloid and Related Disorders. Current Clinical Pathology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-19294-9_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19294-9_31

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-19293-2

  • Online ISBN: 978-3-319-19294-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation